These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21874909)

  • 1. [Progess in the development of VLPs vaccine].
    Cao L; Bi SL
    Bing Du Xue Bao; 2011 Jul; 27(4):378-82. PubMed ID: 21874909
    [No Abstract]   [Full Text] [Related]  

  • 2. The application of virus-like particles to human diseases.
    Buonaguro F; Buonaguro L
    Expert Rev Vaccines; 2013 Feb; 12(2):99. PubMed ID: 23414399
    [No Abstract]   [Full Text] [Related]  

  • 3. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
    Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
    Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Special Issue "Virus-Like Particle Vaccines".
    Vogel M; Bachmann MF
    Viruses; 2020 Aug; 12(8):. PubMed ID: 32784958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genital delivery of virus-like particle and pseudovirus-based vaccines.
    Cuburu N; Chackerian B
    Expert Rev Vaccines; 2011 Sep; 10(9):1245-8. PubMed ID: 21919611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress in virus-like particles technique studies].
    Guo JQ; Zhang ZQ
    Zhongguo Yi Miao He Mian Yi; 2009 Apr; 15(2):167-73. PubMed ID: 20077665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-like particles: potential veterinary vaccine immunogens.
    Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z
    Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus like particle-based vaccines against emerging infectious disease viruses.
    Liu J; Dai S; Wang M; Hu Z; Wang H; Deng F
    Virol Sin; 2016 Aug; 31(4):279-87. PubMed ID: 27405928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subviral particle as vaccine and vaccine platform.
    Tan M; Jiang X
    Curr Opin Virol; 2014 Jun; 6():24-33. PubMed ID: 24662314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice.
    Zhao H; Li HY; Han JF; Deng YQ; Li YX; Zhu SY; He YL; Qin ED; Chen R; Qin CF
    Appl Microbiol Biotechnol; 2013 Dec; 97(24):10445-52. PubMed ID: 24085395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant helical plant virus-based nanoparticles for vaccination and immunotherapy.
    Narayanan KB; Han SS
    Virus Genes; 2018 Oct; 54(5):623-637. PubMed ID: 30008053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine development.
    Wu PC; Lin WL; Wu CM; Chi JN; Chien MS; Huang C
    Appl Microbiol Biotechnol; 2012 Sep; 95(6):1501-7. PubMed ID: 22526782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
    Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
    Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus-like particles: promising platforms with characteristics of DIVA for veterinary vaccine design.
    Liu F; Wu X; Li L; Ge S; Liu Z; Wang Z
    Comp Immunol Microbiol Infect Dis; 2013 Jul; 36(4):343-52. PubMed ID: 23561290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial overview.
    Ertl H; Pulendran B
    Curr Opin Virol; 2011 Oct; 1(4):223-5. PubMed ID: 22440780
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current research status of virus-like particle vaccine].
    Zhang L; Yang YF; Ma X; Zhang YF; Wang Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Sep; 58(9):1404-1414. PubMed ID: 39290024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope engineering and molecular metrics of immunogenicity: a computational approach to VLP-based vaccine design.
    Joshi H; Lewis K; Singharoy A; Ortoleva PJ
    Vaccine; 2013 Oct; 31(42):4841-7. PubMed ID: 23933338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-like particles produced in plants as potential vaccines.
    Scotti N; Rybicki EP
    Expert Rev Vaccines; 2013 Feb; 12(2):211-24. PubMed ID: 23414411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease.
    Shen H; Xue C; Lv L; Wang W; Liu Q; Liu K; Chen X; Zheng J; Li X; Cao Y
    Virus Res; 2013 Dec; 178(2):430-6. PubMed ID: 24050994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-like particles in vaccine development.
    Roldão A; Mellado MC; Castilho LR; Carrondo MJ; Alves PM
    Expert Rev Vaccines; 2010 Oct; 9(10):1149-76. PubMed ID: 20923267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.